Skip to content

Small Diameter TIPS in Patients with Severe Liver Atrophy and Variceal Bleeding

6 Mm Shunt Transjugular Intrahepatic Portosystemic Shunt in Patients with Severe Liver Atrophy and Variceal Bleeding:A Prospective Single-center Randomized Controlled Study

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06589531
Enrollment
120
Registered
2024-09-19
Start date
2024-09-15
Completion date
2028-09-15
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Portal Hypertension Related to Cirrhosis

Keywords

Portal hypertension, TIPS, shunt diameter, hepatic encephalopathy, stent patency

Brief summary

Portal hypertension is the most common complication in patients with end-stage liver cirrhosis. Portal hypertension-related complications, such as variceal bleeding, often lead to a poor prognosis. Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment strategy for managing portal hypertension-related variceal bleeding. However, the appropriate diameter of the covered stent during the TIPS procedure remains a subject of debate. To date, there is a lack of strong evidence regarding the most suitable covered stent diameter. In theory, a shunt with a larger diameter can result in better stent patency, but it can also lead to reduced liver function and a higher incidence of hepatic encephalopathy (HE) after the TIPS procedure. Therefore, the choice of covered stent diameter needs to consider the factors of shunt efficacy and postoperative liver function. At present, the diameters of TIPS-dedicated stents are typically either 8 or 10 mm. Whether stents with these two diameters can meet all the requirements of TIPS procedures is currently unknown. Different races, cirrhosis etiologies, and liver volumes may require different TIPS diameters. For example, in China, most cases of liver cirrhosis are caused by hepatitis B, resulting in the patient having a smaller liver volume. Therefore, in most Chinese studies, the diameters of TIPS stents are mainly 8 mm. Previous studies have shown that TIPS with an 8-mm covered stent has a shunt effect similar to that of a 10-mm covered stent; however, the incidence of postoperative HE is significantly reduced with an 8-mm stent (27% vs. 43%)14. Nevertheless, an 8-mm covered TIPS still has a high incidence of HE. The residual liver volume is small for patients with severe atrophic cirrhosis of the liver, and whether this necessitates a covered TIPS with a smaller diameter requires further study. However, there is still no dedicated TIPS stent that is <8 mm in diameter. In this study, we propose an innovative strategy for the creation of a 6-mm shunt to determine if it can achieve a shunt effect similar to that of an 8-mm covered TIPS and reduce the incidence of HE in patients with severe atrophic liver cirrhosis.

Interventions

DEVICEDuring TIPS operation, shunt diameter or diameter of covered stent

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment strategy for managing portal hypertension-related variceal bleeding. However, the appropriate diameter of the covered stent during the TIPS procedure remains a subject of debate. To date, there is a lack of strong evidence regarding the most suitable covered stent diameter. Due to the lack of a dedicated 6-mm covered stent, we first released a 6-mm diameter stent (SD Express; Boston Scientific Co., or Luminexx; Bard Medical Division) in the liver parenchymal segment of the shunt, and then released an 8-mm TIPS stent (Viatorr; WL Gore &amp; Associates) to create a final 6-mm shunt.

Sponsors

Huang Mingsheng
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Diagnosed as cirrhosis 2. Previous or present endoscopic diagnosis of esophageal and gastric varices bleeding. 3. Child -Pugh score C (≤13) or MELD≤18. 4. Enhanced image measurement of liver volume ≤1000cm3. 5. Have indications for TIPS treatment. 6. Researchers believe that patients have the ability to comply with the research plan. 7. Sign the informed consent form

Exclusion criteria

1. Malignant tumor (including hepatocellular carcinoma) or other diseases that will shorten the life span of patients. 2. Cavernous portal vein 3. Non-cirrhotic portal hypertension (Budd-Chiari syndrome, extrahepatic portal vein obstruction, idiopathic portal hypertension, etc.) 4. Spontaneous dominant hepatic encephalopathy 5 congestive heart failure or severe valvular heart failure 6\. Uncontrollable systemic infection or inflammation 7. Severe pulmonary hypertension 8. Severe renal insufficiency (except hepatogenic renal insufficiency) 9. Rapidly progressing liver failure 10. Contrast agent allergy 11. History of liver transplantation or allogeneic organ transplantation 12. Have a history of TIPS or shunt operation. 13. Pregnancy or lactation 14. Poor compliance 15. Participate in another clinical study.

Design outcomes

Primary

MeasureTime frame
The 1- year rates of rebleedingFrom receiving TIPS to one year after the end of treatment
The 2- year rates of rebleedingFrom receiving TIPS to two year after the end of treatment

Secondary

MeasureTime frameDescription
The 1- year stent patency ratesFrom receiving TIPS to 1 year after the end of treatmentDuring the follow-up, there was no thrombosis in the stent and complications related to portal hypertension caused by stent occlusion.
The 2- year stent patency ratesFrom receiving TIPS to 2 year after the end of treatmentDuring the follow-up, there was no thrombosis in the stent and complications related to portal hypertension caused by stent occlusion.
The 1-year cumulative incidences of overt HEFrom receiving TIPS to 1 year after the end of treatmentHE greater than or equal to 2
The 2-year cumulative incidences of overt HEFrom receiving TIPS to 2 year after the end of treatmentHE greater than or equal to 2

Contacts

Primary ContactHuzheng Yan, doctor
yanhzhdr@163.com8613610176039
Backup ContactMingsheng Huang, doctor
huangmsh@mail.sysu.edu.cn+8613600004855

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026